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Conclusion: Unfavorable mitral valve anatomy represented by high mitral
Echo score ia the main cause of mitral restenosia following MBV.
C3103782 HighRateof RestenoeisFollowingCoronaryAngioplaatyin PatientawithChronicRenal
Failure
F. Gradaua, F.C. Schaebel, K. Ivens, P.Heering, T.W.Jax, M. Leschke,
B.E. Strauer. Clinic of Certlibhgx Heinrich-Heirre Universitift, Dikeeldoti
Germany
Retrospective observational studies suggest a high rate of restenoaiafollow-
ing oaronary angioplasty in patients with end-stage renal disease (ESRD)
undergoing chranic hemcdialyais. A study which investigates the rate of
restenosis in comparison to controls in reapecf to procedural variables and
csrdiovaacular risk factors has not been performed.
In 20 patients on maintenance hemcdialysis and in 20 age- and sex-
matched patients without renal disease corona~ stenosis waa assessed
by computer aseiated quantitative coronary angiography before and after
elective and primarily successful PTCA and at a follow-up caronary angiog-
raptry after 6 months. Plasma concentrations of lipids and fibrinogen were
measured before PTCA.
The rate of restenosis (stenosia =- 50% Iuminal diameter) was 60% in
patients with ESRDand35% in carrtrols.Procedural variables Iikethedegree
of atenosis before (69 =t 9 vs. 65 * 6%) and after PTCA (37 + 6 va. 35 +
11%) as well as the complexity of stenosis dilated did not differ between
both groups. In patients with ESRD concentrations of fibrinogen (463+ 101
VS. wo * 84 r-ngktl,p < 0.001) and triglycerides (269 + 163 vS. 207 &
176 mg/dl, p e 0.01) were significantly elevated in comparison to controls,
while concentrations of total cholesterol (262 +50 vs. 236 +39 mg/dl) LDL-
cholesterol (191 +50 vs. 172 +38 mgldl) and HDL-cholesterol (36+ 15 vs.
42+ 12 m~dl) were comparable.
In this first controlled atudy a high rate of restenosis could be confirmed
in patiente with ESRD. Given the role of reactive thrombogenesis in theearly
phasefollowingcoronaryangioplastyprocoagulantfactorslikeelevationsof
fibrinogenand triglyceridesas a pasaiblemarkerof impairedendogenous
fibrinolyaiamayinfluencetheprocessof restenosisinpatientswithend-stage
ranaldisease.
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I1038-7O]Atheroscleroeisprogre~ionin~u~ia~tsw,t~an~
withoutPost-AngioplaetyReatenosisinQUIET
L. Cashin-Hemphill, R.E. Dinsmore, R.C. Chan, S.N. Williams,
G. Holmvang, H.E. Haber, R.S. Lees for the QUIET Investigators. Boston
Hearf Foundation, Cambridge, MA, USA
The Quinapril Ischemic Event Trial (QUIET) randomized 1750 subjects within
72 hrs of successful PTCA to Quinaprfl 20 mg (Q) or placebo (P) for three
years. The clinical endpaint was time to first cardiac ischemic event in the
full cohort.Followupangiogramswereperfomredin 453 subjects to assess
atherosclerosis progression by QCAin non-intervenedarteries.Resteno-
sis (narrowingwhichwaa ? baselinepre-intervention)wasalsoassessed
visuallyat threeyears.Subjectswho underwent‘ire-do”PTCAduringthe
studywere includedin orderto determinethe total restenosisrate.Of the
453 angicgraphicsubstudysubjecta,164 (76 Q, 86 P, p > 0.05)experi-
enced reatenoaiafor a total rate of 38%.Sixty-oneasymptomaticreetenoses
(13%)were found only at elective three year follow-up angiogram. Early
symptomatic restenasia occurred in 103 subjects (23%). Progression, de-
fined as a 0.40 mm diminution in minimum lumen diameter in a diseased,
non-intervened artery, occurred as followa (p >0.05 for all oamparisana):
AnglogrsphlcProgressors
Placebo(n=229) Quinapril(n=224) Overall(n=453)
Reetanoeie(n= 164) 42J86(50%) 35/ 78(45%) 78/164(48%)
No-Raatenosia(n= 289) 64/143(45%) 67/146(46%) 131/26(45”/6)
We concludethat:1)Sinceatherosclerosisprogressionwaasimilarinthe
restenosiaandno-restenosiagroups, the two procesaeeappear to be patho-
phyaiologically independent. 2) As there was nodifference in reetenosierates
between treatad and placebo groups, the QUIET data suggeets that even
ACE-inhibitors with high tissue affinity do not significantly lessen reatenosis.
~1038-71 I LocalAdministrationof L-7f)3,8fNwitha
CompositePolymerStentReducesPlatelet
DepositioninCanineCoronaryArteries
R.M. Santos, J.-F. Tanguay,K.R. Kruse, J.J. Crowley, J,P. Zidar, Y. Merhi,
E. Garcia-Cantu, R. Bonan, G. C6te, R.S. Stack. Duke University Medicd
Center Durham, NC, USA, Montreal Heart Institute, Montrdal, Quebec,
Canada
Systemic inhibition of platelet glycoprotein llb/llla is effective in reducing 30
day and 6month clinical events following high riakangioplasty, We compared
the effect of L-703,601, a nonpeptide analog of tirofiban, administered Ibcally
with a drug eluting stent to that of standard metal stents on platelet deposition
in canine caronary arteries, Ten mongrel dogs were given 325 mg of aspirin
one day prior to stent implantation. The left anterior descending and left
circumflex arleries were randomly assigned a standard 6 mm slolted metal
tube stent or an 6 mm composite metal/palymer stent incorporated with
L-703,801 (40% by weight). On-line quantitative angiography was uae to
size atenta. Balloon to artery ratios of 1.2-1.3:1 were achieved with infation
pressurea of 10-14 ATM. Platelet deposition determined with ‘tllrr-oxime
waa measured 2 houra after stent implantation. Platelet deposition on drug
loaded stents was significantly less than metal controls: 3.43 (1.91, 3.75) vs.
7.87 (2.53, 11.3) platelets x 107/cm2, p = 0.0186. To determine the effect
of non-dreg loaded polymer, similar studies were performed on 14 animals.
Composite stenta without drug had slightly greater platelet deposition than
metal controls but the difference was not significant: 8.71 (1.97, 12.0) vs.
4.46 (2.43, 17.8) platelete x 107/cm2,p =0.4326. There was no difference in
the proximal reference vessel diameter, the stent minimal lumen diameter or
the stent to artery ratio. Conclusion: Local delivery of L-703,601 is effective
in reducing 2 hour platelet deposition in the canine model of coronary stent
implantation. This study is the first to ahow significantly reduced platelet
deposition by a drug eluting stent compared to standard metal stents.
m103872 Effactof Intracoronary‘Wkridium(1%) on LateQuantitativeAngiographicOutcomesAfterPTCA
J.A. Condado, J.J. Popma, A.J. Lanksy, O. Gurdiel, R. Espinoza, J.G. Brito,
A. Brahimi, B. Burger, L. Hall, M.B. Lwn. Centro Medico De Caracas,
Caracas, Venezuele, Washington Hospital Centec Washington, DC, USA
To evaluate the effect of gamma radiation on the late angiographic outcome
after PTCA, we reviewed the aerial angiograms of 21 patienta (22 lesions)
who received 16-20 Gy 1wlr deliverad via a 3 cm radioactive wire. Quantita-
tive angiography (CMS-GFT) was performed ueing contrast-filled catheters
before and afterPTCA,1-4 montha(N= 12),and>4 months(N= 20) later.
Lesionewerelocatedinthe LAD(50%),RCA(32%),andLCX(18°r&)arteriee.
Lesionlength was9.21 +3.77 mm. After PTCA, 2 patients had small pseudo-
aneurysms. Early (l-4 month) angiography showed 2 total occlusions and 2
(9%) new pseudoaneurysms (one c 2 mm). Serial quantitative angiographic
findings included: MLD = minima/ diameter
Pre Post 1 Month 6 Month
Normal.mm 2.90+0.57 3,01 *6O 2.95+ 0.52 2.90 +0.S0
MLO,Mm 0.9S+0.52 1.94* 0.45 1.61+ 0.s9 1.75* 0.73
0/0Stenosis 66& 16 35& 13 46*2S 41&24
Binary reatenosia(Z 50% follow-up diameter stenosis) occurred in 27%of
lesions, including the 2 patients with early total accluaion. Late Ioas waa 0.19
* 0.78 mm; the loss index (late losa/acute gain) was 0.19. Ten (45%) Iesione
had an increase in lumen diameter during the follow-up period. We conclude
that 1wlrgamma radiation: 1) can be safely performed after PTCA without
an increase in procedural complications, 2) ie associated with infrequent (c
10%) development of late angiographic complications, and 3) appears to
reduce the magnitude of lumen loss after PTCA (late loss= 0.19; loss Index
= 0.19) compared with conventional PTCA.
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Effectivanassof Probucolin Preventing
RestenosisafterPercutaneousTransluminal
CoronaryAngioplastyin SmallSizedCoronary
Arteries:A SubgroupAnalyeiaof the Probucol
AngioplastyReetenosisTrial(PART)
)aida, H. Yamaauchi, Y. Kuwabara 1for the PART GrauD.
Juntendo Universi&, Tokyo,japan, 1Chlba Universi~ Chiba, Japan’
To investigate the effectiveness of Probucol in preventing reetenosie after
PTCA in emall aized vessels, we analysed the angiographic reeults of the
PART study. One hundred and one patienta were randomly aasigned to
Probuod or control group. In Pmbuool group, 1000 mg of Probucol was
administered daily for4weeks priorto PTCAand continued until angicgraphic
